Kohl’s stock exploded 34% on Tuesday, jumping to $21.10 from $15.73 as Q3 earnings delivered an unmistakable turnaround signal. Same-store sales beat expectations, inventory discipline paid off, and management lifted full-year guidance well above Wall Street’s predictions. After a punishing 2024 and years of investor skepticism, the market finally saw proof that the restructuring story
Loading
All posts in "Stock"
Kohl’s stock exploded 34% on Tuesday, jumping to $21.10 from $15.73 as Q3 earnings delivered an unmistakable turnaround signal. Same-store sales beat expectations, inventory discipline paid off, and management lifted full-year guidance well above Wall Street’s predictions. After a punishing 2024 and years of investor skepticism, the market finally saw proof that the restructuring story
165Oklo stock price has nosedived in the past few weeks, erasing over $12 billion in value as the market cap dropped from $25.7 billion in October to $13.7 billion. It has plunged from a high of $193 in October to $88 today. Oklo stock dropped as investors sold shares One reason why the Oklo share
Oklo stock price has nosedived in the past few weeks, erasing over $12 billion in value as the market cap dropped from $25.7 billion in October to $13.7 billion. It has plunged from a high of $193 in October to $88 today. Oklo stock dropped as investors sold shares One reason why the Oklo share
173JPMorgan’s senior analyst Kian Abouhossein has outlined his preferred European bank stocks as investors look ahead to 2026. Despite macroeconomic uncertainty and uneven M&A activity across the sector, Abouhossein believes select names offer compelling value and strong returns. In a recent CNBC interview, Abouhossein said Barclays, UBS, and NatWest stand out on his list, supported
JPMorgan’s senior analyst Kian Abouhossein has outlined his preferred European bank stocks as investors look ahead to 2026. Despite macroeconomic uncertainty and uneven M&A activity across the sector, Abouhossein believes select names offer compelling value and strong returns. In a recent CNBC interview, Abouhossein said Barclays, UBS, and NatWest stand out on his list, supported
173Oracle stock price has suffered a major reversal as concerns about the artificial intelligence (AI) and its soaring debt remain. ORCL dropped to a low of $198, down by over 36% from its highest point this year. Its market cap has dropped from over $967 billion to $530 billion. Oracle stock has crashed amid debt
Oracle stock price has suffered a major reversal as concerns about the artificial intelligence (AI) and its soaring debt remain. ORCL dropped to a low of $198, down by over 36% from its highest point this year. Its market cap has dropped from over $967 billion to $530 billion. Oracle stock has crashed amid debt
194Fairlead Strategies’ founder and technical analysis expert Katie Stockton says the fate of US stocks hinges on how Bitcoin trades over the weekend. The risk-off sentiment driven primarily by macroeconomic uncertainty pushed the world’s largest cryptocurrency by market cap down to the sub $81,000 level this morning. And with it tumbled the benchmark S&P 500
Fairlead Strategies’ founder and technical analysis expert Katie Stockton says the fate of US stocks hinges on how Bitcoin trades over the weekend. The risk-off sentiment driven primarily by macroeconomic uncertainty pushed the world’s largest cryptocurrency by market cap down to the sub $81,000 level this morning. And with it tumbled the benchmark S&P 500
177US stocks surged on Thursday after Nvidia delivered a standout quarterly performance and issued a robust forecast that restored confidence in the artificial intelligence trade underpinning the current bull market. The Dow Jones Industrial Average rallied 621 points, or 1.3%, while the S&P 500 climbed 1.6%. The Nasdaq Composite outperformed with a 2.2% gain. Nvidia
US stocks surged on Thursday after Nvidia delivered a standout quarterly performance and issued a robust forecast that restored confidence in the artificial intelligence trade underpinning the current bull market. The Dow Jones Industrial Average rallied 621 points, or 1.3%, while the S&P 500 climbed 1.6%. The Nasdaq Composite outperformed with a 2.2% gain. Nvidia
178US stocks were little changed on Wednesday as traders looked to Nvidia’s upcoming earnings report to ease concerns about stretched valuations in the artificial intelligence sector. The move followed a four-day slide led by technology shares, which have come under renewed scrutiny as fears of an overheating AI trade intensified. The S&P 500 rose 0.1%,
US stocks were little changed on Wednesday as traders looked to Nvidia’s upcoming earnings report to ease concerns about stretched valuations in the artificial intelligence sector. The move followed a four-day slide led by technology shares, which have come under renewed scrutiny as fears of an overheating AI trade intensified. The S&P 500 rose 0.1%,
180US equities fell sharply on Tuesday as investors retreated from major technology names, and sentiment across risk assets deteriorated further. The Dow Jones Industrial Average declined 466 points, or 1%, while the S&P 500 shed 1%, putting it on course for a fourth straight day of losses — its longest downturn since August. The Nasdaq
US equities fell sharply on Tuesday as investors retreated from major technology names, and sentiment across risk assets deteriorated further. The Dow Jones Industrial Average declined 466 points, or 1%, while the S&P 500 shed 1%, putting it on course for a fourth straight day of losses — its longest downturn since August. The Nasdaq
172Novo Nordisk (NYSE: NVO) has announced sweeping price cuts for its blockbuster GLP-1 drugs, Wegovy and Ozempic, offering patients access to the lowest doses for just $199/month. New cash-paying patients will be able to access its anti-obesity treatments at that price for the first two months, the pharmaceutical behemoth confirmed in a press release today.
Novo Nordisk (NYSE: NVO) has announced sweeping price cuts for its blockbuster GLP-1 drugs, Wegovy and Ozempic, offering patients access to the lowest doses for just $199/month. New cash-paying patients will be able to access its anti-obesity treatments at that price for the first two months, the pharmaceutical behemoth confirmed in a press release today.
190Vinted, Europe’s largest second-hand fashion platform, is in preliminary discussions about a share sale that could value the company at close to €8 billion, according to people familiar with the matter. The secondary transaction would enable some early investors to lock in hefty returns while highlighting the rapid expansion of the Lithuanian start-up, which is
Vinted, Europe’s largest second-hand fashion platform, is in preliminary discussions about a share sale that could value the company at close to €8 billion, according to people familiar with the matter. The secondary transaction would enable some early investors to lock in hefty returns while highlighting the rapid expansion of the Lithuanian start-up, which is
